# Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

> **NCT01017679** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 96 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib 500mg/Gefitinib 250mg

## Key facts

- **NCT ID:** NCT01017679
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-01
- **Final completion:** 2013-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017679, "Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01017679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*